Advertisement

Medical Molecular Morphology

, Volume 49, Issue 2, pp 98–109 | Cite as

Increased phosphorylation of ERK1/2 is associated with worse chemotherapeutic outcome and a poor prognosis in advanced lung adenocarcinoma

  • Ichiro Tsujino
  • Yoko Nakanishi
  • Hisato Hiranuma
  • Tetsuo Shimizu
  • Yukari Hirotani
  • Sumie Ohni
  • Yasushi Ouchi
  • Noriaki Takahashi
  • Norimichi Nemoto
  • Shu Hashimoto
Original Paper

Abstract

Constitutive activation of extracellular signal-regulated kinase (ERK)1/2 pathway, that is activated by various stimuli including growth factors and oncogenic driver mutations, is observed in various cancers. However, the difference of the activated levels of the pathway is still unclear in clinical significances. The aim of this study was to investigate the effect of different ERK1/2 pathway activation, assessed by the expression levels of phosphorylated (p) ERK1/2, on the prognosis of advanced lung adenocarcinoma patients. Paraffin-embedded lung biopsy samples were obtained from 85 lung adenocarcinoma patients. Correlation between pERK1/2 expression levels that were assessed by immunohistochemistry (IHC) analysis and oncogenic driver mutation status, clinicopathological factors, outcome from standard anticancer therapies, and prognosis was investigated. Varying levels of pERK1/2 expression were observed in 68 (80.0 %) patients. The overall survival was significantly reduced in patients with higher pERK1/2 expression in comparison to those with lower expression levels (P = 0.03). In particular, higher pERK1/2 expression levels correlated with worse performance status and worse clinical outcome. Thus, the IHC analysis of pERK1/2 expression levels may predict patient prognosis in advanced lung adenocarcinoma. Inhibition of ERK1/2 pathway activated by various signals may improve the effects of standard chemotherapies and the clinical condition of patients with advanced cancer.

Keywords

Lung adenocarcinoma EGFR KRAS pERK1/2 Chemotherapy Prognosis 

Notes

Acknowledgments

This work was supported by Nihon University School of Medicine 50th Anniversary Fund Research Grant (2012–2013).

References

  1. 1.
    American Cancer Society: Cancer Facts and Figures 2007 (2007) American Cancer Society, AtlantaGoogle Scholar
  2. 2.
    Hirsch FR, Corrin B, Colby TV (2004) World Health Organization classification of tumours. In: Travis WB, Brambilla A, Muller-Hermelinck HK, Harris CC (eds) Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press Lyon, France, p 10Google Scholar
  3. 3.
    Sato M, Shames DS, Gazdar AF, Minna JD (2007) A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2:327–343CrossRefPubMedGoogle Scholar
  4. 4.
    Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175–180CrossRefPubMedGoogle Scholar
  5. 5.
    Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA (2011) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2:135–164CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Geest CR, Coffer PJ (2009) MAPK signaling pathways in the regulation of hematopoiesis. J Leukoc Biol 86:237–250CrossRefPubMedGoogle Scholar
  7. 7.
    Mandal R, Raab M, Matthess Y, Becker S, Knecht R, Strebhardt K (2014) pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner. Mol Oncol 8:232–249CrossRefPubMedGoogle Scholar
  8. 8.
    Rudd CE (2005) MAPK p38: alternative and nonstressful in T cells. Nat Immunol 6:368–370CrossRefPubMedGoogle Scholar
  9. 9.
    Cargnello M, Roux PP (2011) Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75:50–83CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zhao Y, Adjei AA (2014) The clinical development of MEK inhibitors. Nat Rev Clin Oncol 11:385–400CrossRefPubMedGoogle Scholar
  11. 11.
    Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291–3310CrossRefPubMedGoogle Scholar
  12. 12.
    Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA (2005) Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353:133–144CrossRefPubMedGoogle Scholar
  13. 13.
    Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L (2014) Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. Clin Lung Cancer 15:86–92CrossRefPubMedGoogle Scholar
  14. 14.
    Riely GJ, Politi KA, Miller VA, Pao W (2006) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12:7232–7241CrossRefPubMedGoogle Scholar
  15. 15.
    Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M (2013) College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 15:415–453CrossRefPubMedGoogle Scholar
  16. 16.
    Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566CrossRefPubMedGoogle Scholar
  17. 17.
    Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Thunnissen E, van der Oord K, den Bakker M (2014) Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch 464:347–358CrossRefPubMedGoogle Scholar
  19. 19.
    Sonobe M, Kobayashi M, Ishikawa M, Kikuchi R, Nakayama E, Takahashi T, Menju T, Takenaka K, Miyahara R, Huang CL, Okubo K, Bando T, Date H (2012) Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas. Ann Surg Oncol 19:S347–S354CrossRefPubMedGoogle Scholar
  20. 20.
    Johnson ML, Sima CS, Chaft S, Paik PK, Pao W, Kris MG, Ladanyi M, Riely GJ (2013) Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer 119:356–362CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Rosell R, Bivona TG, Karachaliou N (2013) Genetics and biomarkers in personalization of lung cancer treatment. Lancet 382:720–731CrossRefPubMedGoogle Scholar
  22. 22.
    Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, Du Y, Andreeff M, Hortobagyi GN, Hung MC (2010) Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res 70:4709–4718CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA (2013) Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 19:4532–4540CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ventura AP, Radhakrishnan S, Green A, Rajaram SK, Allen AN, O’Briant K, Schummer M, Karlan B, Urban N, Tewari M, Drescher C, Knudsen BS (2010) Activation of the MEK-S6 pathway in high-grade ovarian cancers. Appl Immunohistochem Mol Morphol 18:499–508CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, Müller S, Lewis M, Sica G, Kono S, Brandes JC, Grist WJ, Moreno-Williams R, Beitler JJ, Thomas SM, Chen Z, Shin HJ, Grandis JR, Khuri FR, Chen ZG (2013) Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res 19:1244–1256CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Linder S, Olofsson MH, Herrmann R, Ulukaya E (2010) Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Rev Mol Diagn 10:353–359CrossRefPubMedGoogle Scholar
  27. 27.
    Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR (2004) p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 18:126–131CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Chu PG, Weiss LM (2001) Keratin expression in human tissues and neoplasms. Histopathology 40:403–439CrossRefGoogle Scholar
  29. 29.
    Zheng G, Ettinger DS, Maleki Z (2013) Utility of the quantitative Ki-67 proliferation index and CD56 together in the cytologic diagnosis of small cell lung carcinoma and other lung neuroendocrine tumors. Acta Cytol 57:281–290CrossRefPubMedGoogle Scholar
  30. 30.
    Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Takizawa T, Sunamori M, Handa M, Kondo T, Sasano H (2003) Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab 88:2309–2317CrossRefPubMedGoogle Scholar
  31. 31.
    Nakanishi Y, Shimizu T, Tsujino I, Obana Y, Seki T, Fuchinoue F, Ohni S, Oinuma T, Kusumi Y, Yamada T, Takahashi N, Hashimoto S, Nemoto N (2013) Semi-nested real-time reverse transcription polymerase chain reaction methods for the successful quantitation of cytokeratin mRNA expression levels for the subtyping of non-small-cell-lung carcinoma using paraffin-embedded and microdissected lung biopsy specimens. Acta Histochem Cytochem 46:85–96CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Mizutani G, Nakanishi Y, Watanabe N, Honma T, Obana Y, Seki T, Ohni S, Nemoto N (2012) Expression of somatostatin receptor (SSTR) subtypes (SSTR-1, 2A, 3, 4 and 5) in neuroendocrine tumors using real-time RT-PCR method and immunohistochemistry. Acta Histochem Cytochem 45:167–176CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Ureshino N, Sueoka-Aragane N, Nakamura T, Sato A, Komiya K, Iwanaga K, Mitsuoka M, Takeda Y, Hayashi S, Sueoka E, Kimura S (2011) A fully integrated, automated and rapid detection system for KRAS mutations. Oncol Rep 26:609–613PubMedGoogle Scholar
  34. 34.
    Ureshino N, Aragane N, Nakamura T, Ide M, Mochinaga S, Fukushima N, Hayashi S, Sueoka E, Kimura S (2011) A fully integrated and automated detection system for single nucleotide polymorphisms of UGT1A1 and CYP2C19. Oncol Res 19:111–114CrossRefPubMedGoogle Scholar
  35. 35.
    Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Abe T, Ureshino N, Hayashi S, Hosomi T, Hirai M, Sueoka E, Kimura S (2011) A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J Thoracic Oncol 6:1639–1648CrossRefGoogle Scholar
  36. 36.
    Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S et al (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15:3143–3149CrossRefPubMedGoogle Scholar
  37. 37.
    Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 15(14):6618–6624CrossRefGoogle Scholar
  38. 38.
    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655CrossRefPubMedGoogle Scholar
  39. 39.
    Avruch J (2007) MAP kinase pathways: the first twenty years. Biochem Biophys Acta 1773:1150–1160CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Ochi N, Takigawa N, Harada D, Yasugi M, Ichihara E, Hotta K, Tabata M, Tanimoto M, Kiura K (2014) Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Exp Cell Res 322:168–177CrossRefPubMedGoogle Scholar
  41. 41.
    Kubota Y, O’Grady P, Saito H, Takekawa M (2011) Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation. Nat Cell Biol 13:282–291CrossRefPubMedGoogle Scholar
  42. 42.
    Tetsu O, McCormick F (2003) Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3:233–245CrossRefPubMedGoogle Scholar
  43. 43.
    Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A (2007) Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PloS Med 4:1681–1689CrossRefPubMedGoogle Scholar
  44. 44.
    Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, Ganchev H, Pover G, Morris C, Tzekova V (2010) A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 5:1630–1636CrossRefPubMedGoogle Scholar
  45. 45.
    Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13:1576–1583CrossRefPubMedGoogle Scholar
  46. 46.
    Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios CH, Franke FA, Grinsted L, Smith PD, Zazulina V, Smith IC and Crino L (2012) Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol 30: suppl; abstr 7503Google Scholar
  47. 47.
    Sholl LM (2015) Biomarkers in lung adenocarcinoma: a decade of progress. Arch Pathol Lab Med. 139:469–480CrossRefPubMedGoogle Scholar
  48. 48.
    Devarakonda S, Morgensztern D, Govindan R (2015) Genomic alterations in lung adenocarcinoma. Lancet Oncol 16(7):342–351CrossRefGoogle Scholar
  49. 49.
    Klempner SJ, Ignatius Ou SH, Costa DB, VanderLaan PA, Sanford EM, Schrock A, Gay L, Ali SM, Miller VA (2015) The clinical use of genomic profiling to distinguish intrapulmonary metastases from synchronous primaries in non-small-cell lung cancer: a mini-review. Clin Lung Cancer 16(5):334–339CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society for Clinical Molecular Morphology 2015

Authors and Affiliations

  • Ichiro Tsujino
    • 1
  • Yoko Nakanishi
    • 2
  • Hisato Hiranuma
    • 1
  • Tetsuo Shimizu
    • 1
  • Yukari Hirotani
    • 2
  • Sumie Ohni
    • 2
  • Yasushi Ouchi
    • 1
  • Noriaki Takahashi
    • 1
  • Norimichi Nemoto
    • 2
  • Shu Hashimoto
    • 1
  1. 1.Division of Respiratory Medicine, Department of Internal MedicineNihon University School of MedicineTokyoJapan
  2. 2.Division of Pathology, Department of Pathology and MicrobiologyNihon University School of MedicineTokyoJapan

Personalised recommendations